Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tinostamustine phase 2 study in advanced solid tumors
NL-OMON50797Phase 2Withdrawn
- Sponsor
- Mundipharma
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tinostamustine in Nonhematologic neoplasms, small cell lung cancer (SCLC), soft tissue sarcoma (STS), triple-negative breast cancer (TNBC), ovarian cancer, sponsored by Mundipharma. Planned start May 2021; status: withdrawn.
02
Drugs
tinostamustine
03
Conditions
Nonhematologic neoplasmssmall cell lung cancer (SCLC)soft tissue sarcoma (STS)triple-negative breast cancer (TNBC)ovarian cancer
Beyond the preview
Go deeper on NL-OMON50797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50797.